Premium Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 29 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.10 M
About Premium Pharmaceuticals
Company Details
-
Location
Ludhiana, Punjab, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232PB1995PTC016068
-
Company No.
016068
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Mar 1995
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Premium Pharmaceuticals?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Keshav Sharma
![]() |
Director | 20-Oct-2018 | Current |
Anuradha Sharma
![]() |
Director | 21-Mar-1995 | Current |
Financial Performance of Premium Pharmaceuticals.
Premium Pharmaceuticals Pvt Ltd, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
![Graph illustrating revenue growth over time](/Images/financial/revenue-growth.webp)
![Graph showing profit and loss trends over time](/Images/financial/profit-loss.webp)
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Premium Pharmaceuticals?
In 2017, Premium Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
![Shareholding Indicator graph](/Images/tcc-login/Shareholding-Indiacator-1200.webp)
Charges (Loans)
₹0
₹3.10 M
Charges Breakdown by Lending Institutions
- Bank Of India : 0.31 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
06 Feb 2002 | Bank Of India | ₹2.00 M | Satisfied |
06 Feb 2002 | Bank Of India | ₹0.20 M | Satisfied |
28 Feb 1997 | Bank Of India | ₹0.20 M | Satisfied |
28 Feb 1997 | Bank Of India | ₹0.70 M | Satisfied |
How Many Employees Work at Premium Pharmaceuticals?
Unlock and access historical data on people associated with Premium Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
![Graph showing employee growth trends](/Images/tcc-login/Employee-Graph.webp)
Deals i
![Graph showing company valuation over time](/Images/tcc-login/Valuation-Graph-small.webp)
Gain comprehensive insights into the Deals and Valuation data of Premium Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Premium Pharmaceuticals's trajectory.
Rating
![Graph displaying rating trends over time](/Images/tcc-login/Rating-Graph-small.webp)
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
![Alert Indicator](/Images/tcc-login/Alert-Indicator-small.webp)
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.